Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: A multi-site, multi-compound study

Proteomics

Volumn 10, Issue 8, 2010, Pages 1592-1608

  Collins, Ben C ^a   Sposny, Alexandra ^b   McCarthy, Diane ^c   Brandenburg, Arnd ^d   Woodbury, Ronald ^c   Pennington, Stephen R ^a   Gautier, Jean Charles ^e   Hewitt, Phillip ^b   Gallagher, William M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b Merck Serono GmbH   (Germany)

^c BIO RAD LABORATORIES   (United States)

^d GENEDATA AG   (Switzerland)

^e SANOFI   (France)

Author keywords

Animal proteomics; Pre clinical safety; SELDI TOF MS; Systems toxicology; Toxicoproteomics

Indexed keywords

BIOLOGICAL MARKER; LIVER PROTEIN; PLASMA PROTEIN; ALBUMIN; BETA 2 MICROGLOBULIN; GENTAMICIN; IMMUNOGLOBULIN G; TROGLITAZONE;

ACCURACY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; METABONOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RAT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TOXICITY TESTING; TRANSCRIPTOMICS; IN VIVO STUDY; REPRODUCIBILITY; TISSUE SECTION;

ANIMALS; BIOLOGICAL MARKERS; PROTEOME; RATS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

ANIMALIA; RATTUS;

EID: 77951063166     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200900608     Document Type: Article

References (41)

1. Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates? Nat. Rev. 2004, 3, 711-715. (Pubitemid 39173511)
2. Kramer, J. A., Sagartz, J. E., Morris, D. L., The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev.2007, 6, 636-649.
3. DiMasi, J. A., Hansen, R. W., Grabowski, H. G., The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22, 151-185.
4. Waters, M. D., Fostel, J. M., Toxicogenomics and systems toxicology: aims and prospects. Nat. Rev. Genet. 2004, 5, 936-948.
5. Heijne, W. H., Kienhuis, A. S., van Ommen, B., Stierum, R. H., Groten, J. P., Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev. Proteomics 2005, 2, 767-780.
6. Suter, L., Babiss, L. E., Wheeldon, E. B., Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 2004, 11, 161-171. (Pubitemid 38300287)
7. Maggioli, J., Hoover, A., Weng, L., Toxicogenomic analysis methods for predictive toxicology. J. Pharmacol. Toxicol. Methods 2005, 53, 31-37. (Pubitemid 43052701)
8. Merrick, B. A., The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. Brief. Funct. Genomic Proteomics 2008, 7, 35-49.
9. Wetmore, B. A., Merrick, B. A., Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 2004, 32, 619-642.
10. Collins, B. C., Clarke, A., Kitteringham, N. R., Gallagher, W. M., Pennington, S. R., Use of proteomics for the discovery of early markers of drug toxicity. Expert Opin. Drug Metab. Toxicol. 2007, 3, 689-704. (Pubitemid 351320637)
11. Craig, A., Sidaway, J., Holmes, E., Orton, T. et al., Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res.2006, 5, 1586-1601. (Pubitemid 44036133)
12. Gallagher, W. M., Tweats, D., Koenig, J., Omic profiling for drug safety assessment: current trends and public-private partnerships. Drug Discov. Today 2009, 14, 337-342.
13. Mulrane, L., Rexhepaj, E., Smart, V., Callanan, J. J. et al., Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group. Exp. Toxicol. Pathol. 2008, 60, 235-245.
14. Tang, N., Tornatore, P., Weinberger, S. R., Current developments in SELDI affinity technology. Mass Spectrom. Rev. 2004, 23, 34-44.
15. Rai, A. J., Stemmer, P. M., Zhang, Z., Adam, B. L. et al., Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005, 5, 3467-3474. (Pubitemid 41192051)
16. Beyer, S., Walter, Y., Hellmann, J., Kramer, P. J. et al., Comparison of software tools to improve the detection of carcinogen induced changes in the rat liver proteome by analyzing SELDI-TOF-MS spectra. J. Proteome Res. 2006, 5, 254-261. (Pubitemid 43222293)
17. Bjornstad, A., Larsen, B. K., Skadsheim, A., Jones, M. B., Andersen, O. K., The potential of ecotoxicoproteomics in environmental monitoring: biomarker profiling in mussel plasma using ProteinChip array technology. J. Toxicol. Environ. Health 2006, 69, 77-96. (Pubitemid 41715159)
18. Dare, T. O., Davies, H. A., Turton, J. A., Lomas, L. et al., Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. Electrophoresis 2002, 23, 3241-3251. (Pubitemid 35154174)
19. Hogstrand, C., Balesaria, S., Glover, C. N., Application of genomics and proteomics for study of the integrated response to zinc exposure in a non-model fish species, the rainbow trout. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2002, 133, 523-535. (Pubitemid 35441079)
20. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
21. Fella, K., Gluckmann, M., Hellmann, J., Karas, M. et al., Use of two-dimensional gel electrophoresis in predictive toxicology: identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics 2005, 5, 1914-1927. (Pubitemid 40686236)
22. Candiano, G., Bruschi, M., Musante, L., Santucci, L. et al., Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004, 25, 1327-1333. (Pubitemid 38801651)
23. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
24. Zhu, Z., Edwards, R. J., Boobis, A. R., Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity). Toxicol. Lett. 2008, 181, 93-103.
25. Petricoin, E. F., Rajapaske, V., Herman, E. H., Arekani, A. M. et al., Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol. Pathol. 2004, 32, 122-130. (Pubitemid 38437576)
26. Boll, M., Weber, L. W., Becker, E., Stampfl, A., Hepatocyte damage induced by carbon tetrachloride: inhibited lipoprotein secretion and changed lipoprotein composition. Z. Naturforsch. B 2001, 56, 283-290. (Pubitemid 32430530)
27. Chao, Y. S., Pickett, C. B., Yamin, T. T., Guo, L. S. et al., Phenobarbital induces rat liver apolipoprotein A-I mRNA. Mol. Pharmacol. 1985, 27, 394-398.
28. Kleno, T. G., Leonardsen, L. R., Kjeldal, H. O., Laursen, S. M. et al., Mechanisms of hydrazine toxicity in rat liver investigated by proteomics and multivariate data analysis. Proteomics 2004, 4, 868-880.
29. Amacher, D. E., Adler, R., Herath, A., Townsend, R. R., Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin. Chem. 2005, 51, 1796-1803. (Pubitemid 41368169)
30. Salinas, A. E., Wong, M. G., Glutathione S-transferases - a review. Curr. Med. Chem. 1999, 6, 279-309.
31. Shaw, M., The use of histologically defined specific biomarkers in drug development with special reference to the glutathione S-transferases. Cancer Biomark 2005, 1, 69-74.
32. Ozer, J., Ratner, M., Shaw, M., Bailey, W., Schomaker, S., The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245, 194-205.
33. Schuierer, M. M., Bataille, F., Weiss, T. S., Hellerbrand, C., Bosserhoff, A. K., Raf kinase inhibitor protein is down-regulated in hepatocellular carcinoma. Oncol. Rep. 2006, 16, 451-456.
34. Nilsen, A. J., Landin, M. A., Haug, K. H., Fonnum, F. et al., Comparative hepatic gene expression profiling of rats treated with 1H,1H,2H,2H- heptadecafluorodecan-1-ol or with pentadecafluorooctanoic acid. Physiol. Genomics 2008, 34, 285-303. (Pubitemid 352758844)
35. Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E. et al., A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53, 1067-1074. (Pubitemid 46867523)
36. Boschetti, E., Righetti, P. G., The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J. Proteomics 2008, 71, 255-264.
37. America, A. H., Cordewener, J. H., Comparative LC-MS: a landscape of peaks and valleys. Proteomics 2008, 8, 731-749.
38. Kuster, B., Schirle, M., Mallick, P., Aebersold, R., Scoring proteomes with proteotypic peptide probes. Nat. Rev. 2005, 6, 577-583. (Pubitemid 40943048)
39. Tiss, A., Smith, C., Camuzeaux, S., Kabir, M. et al., Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. Proteomics 2007, 7, 77-89. (Pubitemid 351547773)
40. Callesen, A. K., Madsen, J. S., Vach, W., Kruse, T. A. et al., Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics 2009, 9, 1428-1441.
41. Albrethsen, J., Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 2007, 53, 852-858. (Pubitemid 46744240)